TLX300 / Telix, Eli Lilly - LARVOL DELTA

ZOLAR: 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Trial completion date: Aug 2026 ➔ Dec 2027 | Trial primary completion date: Mar 2026 ➔ Oct 2027

First-in-human • Trial completion date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma (GlobeNewswire) - "Telix Pharmaceuticals Limited...announces that a first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia."

Trial status • Soft Tissue Sarcoma

ZOLAR: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2024 ➔ Oct 2024 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Enrollment open • Trial initiation date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PDGFRA

ZOLAR: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd

New P1 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • PDGFRA

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical (PRNewswire) - "Telix Pharmaceuticals Limited...announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progress to first-in-human clinical studies based on these highly encouraging results.... Furthermore, olaratumab radiolabelled with therapeutic radionuclide payloads has demonstrated in vivo efficacy with significant reduction in tumour volumes in relevant disease models, even after administration of a single dose."

Preclinical • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor